Role of the voltage‑gated sodium channel Nav1.6 in glioma and candidate drugs screening

Ai,Yong; Ai,Yong; Zhang,Xudong; Zhang,Xudong; Hu,Xudong; Hu,Xudong; Gao,Jinte; Gao,Jinte; Liu,Jiyuan; Liu,Jiyuan; Ou,Shaowu; Ou,Shaowu; Wang,Jun; Wang,Jun

doi:10.3892/ijmm.2023.5249

Role of the voltage‑gated sodium channel Nav1.6 in glioma and candidate drugs screening

Authors:
- Yong Ai
- Xudong Zhang
- Xudong Hu
- Jinte Gao
- Jiyuan Liu
- Shaowu Ou
- Jun Wang
View Affiliations

Affiliations: Department of Neurosurgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110000, P.R. China, Department of Neurosurgery, The Fourth Hospital of China Medical University, Shenyang, Liaoning 110084, P.R. China
Published online on: April 13, 2023 https://doi.org/10.3892/ijmm.2023.5249
Article Number: 46
Copyright: © Ai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gliomas remain a clinical challenge, common and fatal. Treatment of glioblastoma remains elusive, and researchers have focused on discovering new mechanisms and drugs. It has been well established that the expression of voltage‑gated sodium channels (VGSCs) is abnormally increased in numerous malignancies and, in general, is rarely expressed in the corresponding normal tissues. This suggests that ion channel activity appears to be associated with malignant progression of tumors. VGSCs remain largely unknown as to how their activity leads to an increase in cancer cell activity or invasiveness. Certain sodium ion channel subtypes (for instance, Nav1.5 and Nav1.7) are associated with metastasis and invasion in cancers including breast and colorectal cancers. A previous study by the authors explored the expression of certain ion channels in glioma, but there are few studies related to Nav1.6. The current study aimed to elucidate the expression and role of Nav1.6 in glioma and to screen potential drugs for the treatment of glioma by virtual screening and drug sensitivity analysis. Nav1.6 relative expression of mRNA and protein was determined by reverse transcription‑quantitative PCR and western blot analysis. Cell proliferation was determined by Cell Counting Kit‑8 assay. Cell migration was assessed by cellular wound healing assay. Cell invasion and apoptosis were detected by Transwell cell invasion assay and flow cytometry. Last but not least, FDA‑approved drugs were screened using virtual screening, molecular docking and NCI‑60 drug sensitivity analyses based on the expression and structure of Nav1.6. In glioma cells, Nav1.6 was significantly upregulated and expressed mostly in the cytoplasm and cell membrane; its expression was positively correlated with pathological grade. A172 and U251 cells exhibited reduced proliferation, migration and invasion when Nav1.6 expression was knocked down, and apoptosis was increased. TNF‑α (100 pg/ml) acting on glioma cells was found to upregulate the expression level of Nav1.6, and TNF‑α was involved in the process of Nav1.6 promoting malignant progression of glioma. Finally, certain FDA‑approved drugs were identified by virtual screening and drug sensitivity analysis. In conclusion, the present study demonstrated the expression and role of Nav1.6 in glioma and identified several FDA‑approved drugs that are highly correlated with Nav1.6 and could be candidate drugs for patients with glioma.

View Figures

View References

1	Lapointe S, Perry A and Butowski NA: Primary brain tumours in adults. Lancet. 392:432–446. 2018. View Article : Google Scholar : PubMed/NCBI
2	Luo Q, Wu T, Wu W, Chen G, Luo X, Jiang L, Tao H, Rong M, Kang S and Deng M: The functional role of voltage-gated sodium channel Nav1.5 in metastatic breast cancer. Front Pharmacol. 11:11112020. View Article : Google Scholar : PubMed/NCBI
3	Altamura C, Greco MR, Carratu MR and Cardone RA: Desaphy JF. Emerging roles for ion channels in ovarian cancer: Pathomechanisms and pharmacological treatment. Cancers (Basel). 13:6682021. View Article : Google Scholar : PubMed/NCBI
4	Brummelhuis IS, Fiascone SJ, Hasselblatt KT and Frendl G: Elias KM. Voltage-gated sodium channels as potential biomarkers and therapeutic targets for epithelial ovarian cancer. Cancers (Basel). 13:54372021. View Article : Google Scholar : PubMed/NCBI
5	Brackenbury WJ: Voltage-gated sodium channels and metastatic disease. Channels (Austin). 6:352–361. 2012. View Article : Google Scholar : PubMed/NCBI
6	Liu J, Tan H, Yang W, Yao S and Hong L: The voltage-gated sodium channel Nav1.7 associated with endometrial cancer. J Cancer. 10:4954–4960. 2019. View Article : Google Scholar :
7	Lin S, Lv Y, Xu J, Mao X, Chen Z and Lu W: Over-expression of Nav1.6 channels is associated with lymph node metastases in colorectal cancer. World J Surg Oncol. 17:1752019. View Article : Google Scholar : PubMed/NCBI
8	Black JA, Liu S and Waxman SG: Sodium channel activity modulates multiple functions in microglia. Glia. 57:1072–1081. 2009. View Article : Google Scholar
9	Takayasu T, Kurisu K, Esquenazi Y and Ballester LY: Ion channels and their role in the pathophysiology of gliomas. Mol Cancer Ther. 19:1959–1969. 2020. View Article : Google Scholar : PubMed/NCBI
10	Wang J, Ou SW, Wang YJ, Kameyama M, Kameyama A and Zong ZH: Analysis of four novel variants of Nav1.5/SCN5A cloned from the brain. Neurosci Res. 64:339–347. 2009. View Article : Google Scholar : PubMed/NCBI
11	Guan G, Zhao M, Xu X, Boczek T, Mao X, Li Z, Gao Q, Li J, Zhao D, Niu W, et al: Abnormal changes in voltage-gated sodium channels subtypes NaV1.1, NaV1.2, NaV1.3, NaV1.6 and CaM/CaMKII pathway in low-grade astrocytoma. Neurosci Lett. 674:148–155. 2018. View Article : Google Scholar : PubMed/NCBI
12	Xing D, Wang J, Ou S, Wang Y, Qiu B, Ding D, Guo F and Gao Q: Expression of neonatal Nav1.5 in human brain astrocytoma and its effect on proliferation, invasion and apoptosis of astrocytoma cells. Oncol Rep. 31:2692–2700. 2014. View Article : Google Scholar : PubMed/NCBI
13	Mao W, Zhang J, Korner H, Jiang Y and Ying S: The emerging role of voltage-gated sodium channels in tumor biology. Front Oncol. 9:1242019. View Article : Google Scholar : PubMed/NCBI
14	Xu L, Ding X, Wang T, Mou S, Sun H and Hou T: Voltage-gated sodium channels: Structures, functions, and molecular modeling. Drug Discov Today. 24:1389–1397. 2019. View Article : Google Scholar : PubMed/NCBI
15	Wang J, Ou SW and Wang YJ: Distribution and function of voltage-gated sodium channels in the nervous system. Channels (Austin). 11:534–554. 2017. View Article : Google Scholar : PubMed/NCBI
16	Diaz-Garcia A and Varela D: Voltage-Gated K(+)/Na(+) channels and scorpion venom toxins in cancer. Front Pharmacol. 11:9132020. View Article : Google Scholar : PubMed/NCBI
17	Schreiber JM, Tochen L, Brown M, Evans S, Ball LJ, Bumbut A, Thewamit R, Whitehead MT, Black C, Boutzoukas E, et al: A multi-disciplinary clinic for SCN8A-related epilepsy. Epilepsy Res. 159:1062612020. View Article : Google Scholar
18	Bennett DL, Clark AJ, Huang J, Waxman SG and Dib-Hajj SD: The role of Voltage-gated sodium channels in pain signaling. Physiol Rev. 99:1079–1151. 2019. View Article : Google Scholar : PubMed/NCBI
19	Alrashdi B, Dawod B, Schampel A, Tacke S, Kuerten S, Marshall JS and Côté PD: Nav1.6 promotes inflammation and neuronal degeneration in a mouse model of multiple sclerosis. J Neuroinflammation. 16:2152019. View Article : Google Scholar : PubMed/NCBI
20	Menezes LFS, Sabia Junior EF, Tibery DV, Carneiro LDA and Schwartz EF: Epilepsy-Related Voltage-gated sodium channelopathies: A review. Front Pharmacol. 11:12762020. View Article : Google Scholar : PubMed/NCBI
21	Angus M and Ruben P: Voltage gated sodium channels in cancer and their potential mechanisms of action. Channels (Austin). 13:400–409. 2019. View Article : Google Scholar : PubMed/NCBI
22	Besson P, Driffort V, Bon E, Gradek F, Chevalier S and Roger S: How do voltage-gated sodium channels enhance migration and invasiveness in cancer cells? Biochim Biophys Acta. 1848:2493–2501. 2015. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
24	FDA-Approved & Pharmacopeia Drug Library. https://www.targetmol.com/compound-library/fda_approved_&_pharmacopeia_drug_library Accessed March 8, 2022.
25	Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A, et al: Highly accurate protein structure prediction with AlphaFold. Nature. 596:583–589. 2021. View Article : Google Scholar : PubMed/NCBI
26	Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, Yuan D, Stroe O, Wood G, Laydon A, et al: AlphaFold protein structure database: Massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 50:D439–D444. 2022. View Article : Google Scholar :
27	Kawabata T: Detection of multiscale pockets on protein surfaces using mathematical morphology. Proteins. 78:1195–1211. 2010. View Article : Google Scholar
28	Allen WJ, Fochtman BC, Balius TE and Rizzo RC: Customizable de novo design strategies for DOCK: Application to HIVgp41 and other therapeutic targets. J Comput Chem. 38:2641–2663. 2017. View Article : Google Scholar : PubMed/NCBI
29	Wallace AC, Laskowski RA and Thornton JM: LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8:127–134. 1995. View Article : Google Scholar : PubMed/NCBI
30	Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, Doroshow J and Pommier Y: CellMiner: A web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res. 72:3499–3511. 2012. View Article : Google Scholar : PubMed/NCBI
31	Cheng S, Wang HN, Xu LJ, Li F, Miao Y, Lei B, Sun X and Wang Z: Soluble tumor necrosis factor-alpha-induced hyperexcitability contributes to retinal ganglion cell apoptosis by enhancing Nav1.6 in experimental glaucoma. J Neuroinflammation. 18:1822021. View Article : Google Scholar : PubMed/NCBI
32	Pan X, Li Z, Zhou Q, Shen H, Wu K, Huang X, Chen J, Zhang J, Zhu X, Lei J, et al: Structure of the human voltage-gated sodium channel Na_v1.4 in complex with β1. Science. 362:eaau24862018. View Article : Google Scholar
33	Schrey M, Codina C, Kraft R, Beetz C, Kalff R, Wölfl S and Patt S: Molecular characterization of voltage-gated sodium channels in human gliomas. Neuroreport. 13:2493–2498. 2002. View Article : Google Scholar : PubMed/NCBI
34	Catterall WA, Lenaeus MJ and Gamal El-Din TM: Structure and pharmacology of voltage-gated sodium and calcium channels. Annu Rev Pharmacol Toxicol. 60:133–154. 2020. View Article : Google Scholar
35	Clatot J, Ziyadeh-Isleem A, Maugenre S, Denjoy I, Liu H, Dilanian G, Hatem SN, Deschênes I, Coulombe A, Guicheney P and Neyroud N: Dominant-negative effect of SCN5A N-terminal mutations through the interaction of Na(v)1.5 α-subunits. Cardiovasc Res. 96:53–63. 2012. View Article : Google Scholar : PubMed/NCBI
36	Hernandez-Plata E, Ortiz CS, Marquina-Castillo B, Medina-Martinez I, Alfaro A, Berumen J, Rivera M and Gomora JC: Overexpression of NaV 1.6 channels is associated with the invasion capacity of human cervical cancer. Int J Cancer. 130:2013–2023. 2012. View Article : Google Scholar
37	Yang Y, Luo Z, Hao Y, Ba W, Wang R, Wang W, Ding X and Li C: mTOR-mediated Na⁺/Ca2⁺ exchange affects cell proliferation and metastasis of melanoma cells. Biomed Pharmacother. 92:744–749. 2017. View Article : Google Scholar : PubMed/NCBI
38	Ding HH, Zhang SB, Lv YY, Ma C, Liu M, Zhang KB, Ruan XC, Wei JY, Xin WJ and Wu SL: TNF-α/STAT3 pathway epigenetically upregulates Nav1.6 expression in DRG and contributes to neuropathic pain induced by L5-VRT. J Neuroinflammation. 16:292019. View Article : Google Scholar
39	Lei Q, Gu H, Li L, Wu T, Xie W, Li M and Zhao N: TNIP1-mediated TNF-α/NF-κB signalling cascade sustains glioma cell proliferation. J Cell Mol Med. 24:530–538. 2020. View Article : Google Scholar
40	Onganer PU and Djamgoz MB: Small-cell lung cancer (human): Potentiation of endocytic membrane activity by voltage-gated Na(+) channel expression in vitro. J Membr Biol. 204:67–75. 2005. View Article : Google Scholar : PubMed/NCBI
41	Reddy Chichili VP, Xiao Y, Seetharaman J, Cummins TR and Sivaraman J: Structural basis for the modulation of the neuronal voltage-gated sodium channel NaV1.6 by calmodulin. Sci Rep. 3:24352013. View Article : Google Scholar : PubMed/NCBI
42	Bulling A, Brucker C, Berg U, Gratzl M and Mayerhofer A: Identification of voltage-activated Na⁺ and K⁺ channels in human steroid-secreting ovarian cells. Ann N Y Acad Sci. 868:77–79. 1999. View Article : Google Scholar : PubMed/NCBI
43	Anderson KJ, Cormier RT and Scott PM: Role of ion channels in gastrointestinal cancer. World J Gastroenterol. 25:5732–5772. 2019. View Article : Google Scholar : PubMed/NCBI
44	Huang K, Wang X, Liu Y and Zhao Y: CRAC channel is inhibited by neomycin in a Ptdlns(4,5)P2-independent manner. Cell Biochem Funct. 33:97–100. 2015. View Article : Google Scholar : PubMed/NCBI
45	Mikkelsen NE, Brännvall M, Virtanen A and Kirsebom LA: Inhibition of RNase P RNA cleavage by aminoglycosides. Proc Natl Acad Sci USA. 96:6155–6160. 1999. View Article : Google Scholar : PubMed/NCBI
46	Tang C, Gong L, Lvzi X, Qiu K, Zhang Z and Wan L: Echinacoside inhibits breast cancer cells by suppressing the Wnt/β-catenin signaling pathway. Biochem Biophys Res Commun. 526:170–175. 2020. View Article : Google Scholar : PubMed/NCBI
47	Zhu M, Lu C and Li W: Transient exposure to echinacoside is sufficient to activate Trk signaling and protect neuronal cells from rotenone. J Neurochem. 124:571–580. 2013. View Article : Google Scholar
48	Zheng A, Kallio A and Härkönen P: Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen. Endocrinology. 148:2764–2777. 2007. View Article : Google Scholar : PubMed/NCBI
49	Feil S, Valtcheva N and Feil R: Inducible Cre mice. Methods Mol Biol. 530:343–363. 2009. View Article : Google Scholar : PubMed/NCBI
50	Rondón-Lagos M, Rangel N, Di Cantogno LV, Annaratone L, Castellano I, Russo R, Manetta T, Marchiò C and Sapino A: Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes. Endocr Relat Cancer. 23:635–650. 2016. View Article : Google Scholar : PubMed/NCBI
51	Odia Y, Kreisl TN, Aregawi D, Innis EK and Fine HA: A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas. J Neurooncol. 125:191–195. 2015. View Article : Google Scholar : PubMed/NCBI
52	Lien EA, Solheim E and Ueland PM: Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res. 51:4837–4844. 1991.PubMed/NCBI
53	Novick AM, Scott AT, Neill Epperson C and Schneck CD: Neuropsychiatric effects of tamoxifen: Challenges and opportunities. Front Neuroendocrinol. 59:1008692020. View Article : Google Scholar : PubMed/NCBI